Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 5Phase 3 1

Status

Recruiting 7

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Tumor-Agnostic 1Breast 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 2Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 42Specimen Handling 38Magnetic Resonance Spectroscopy 30Carboplatin 30Cyclophosphamide 27Biopsy 25Nivolumab 23Dexamethasone 22fludarabine 21Gemcitabine 19Bevacizumab 15Paclitaxel 14Temozolomide 13Pemetrexed 13Docetaxel 13Cisplatin 13atezolizumab 12Ipilimumab 12Rituximab 11venetoclax 10Prednisone 10Lenalidomide 9Injections 9Fulvestrant 9lenvatinib 8X-Rays 8Vincristine 8Trastuzumab 8Oxaliplatin 8Fluorouracil 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1/2 × patritumab deruxtecan × 30 days × Clear all
NCT06596694 2026-06-01

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
180 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT07286149 2026-05-26

MK-3475-01F

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
190 enrolled
Thoracic

Lung Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
81 enrolled
Breast

Breast Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
450 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡